{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-21-225700","form_type":"8-K","ticker":"RVTY","cik":"0000031791","company_name":"REVVITY, INC.","filed_at":"2021-07-27T23:59:59+00:00","discovered_at":"2026-05-14T18:04:20.325817+00:00","generated_at":"2026-06-30T02:18:45.490657+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"PerkinElmer to acquire BioLegend for $5.25B; expects $0.30 adjusted EPS accretion in first full year","bullets":["Purchase price ~$5.25B; 59.5% cash and 40.5% stock at $156.3561/share.","BioLegend estimated 2022 revenues ~$380M with mid-teens-plus growth.","Expected $0.30 adjusted EPS accretion in 1st full year, >$0.50 in 2nd year.","Revenue synergies expected $100M annually by 5th year post-close; no significant cost synergies planned.","Bridge financing of $3.3B committed by Goldman Sachs; no financing condition."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-21-225700","json":"https://secwatch.observer/filing/0001193125-21-225700.json","markdown":"https://secwatch.observer/filing/0001193125-21-225700.md","text":"https://secwatch.observer/filing/0001193125-21-225700.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/0001193125-21-225700-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/31791/000119312521225700/d205775d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T02:18:45.490657+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}